Using the principles outlined in ICH Q3D and training modules we will:
• Present a series of risk assessments based on actual products.
• Examining different routes of administration.
• Through this seek to highlight there is more than one approach, illustrated through the examples shown.
• Marketing application – example summary and proposed location.
• Approach to products during clinical development.
Continue at: https://www.ema.europa.eu/documents/presentation/presentation-elemental-impurity-risk-assessment-case-studies-andrew-teasdale-laura-rutter_en.pdf
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link